Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 406269, 10 pages
http://dx.doi.org/10.1155/2015/406269
Research Article

Association between Serum Soluble Klotho Levels and Mortality in Chronic Hemodialysis Patients

1Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan
2Department of Nephrology, Japanese Red Cross Koga Hospital, Koga, Ibaraki, Japan
3Division of Anti-Aging Medicine, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan

Received 26 July 2015; Revised 4 October 2015; Accepted 13 October 2015

Academic Editor: Darío A. Castroviejo

Copyright © 2015 Naoko Otani-Takei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. C. Hu, K. Shiizaki, M. Kuro-O, and O. W. Moe, “Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism,” Annual Review of Physiology, vol. 75, pp. 503–533, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Kuro-o, Y. Matsumura, H. Aizawa et al., “Mutation of the mouse klotho gene leads to a syndrome resembling ageing,” Nature, vol. 390, no. 6655, pp. 45–51, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Imura, A. Iwano, O. Tohyama et al., “Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane,” FEBS Letters, vol. 565, no. 1–3, pp. 143–147, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. M. C. Hu, M. Shi, J. Zhang et al., “Klotho deficiency causes vascular calcification in chronic kidney disease,” Journal of the American Society of Nephrology, vol. 22, no. 1, pp. 124–136, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Akimoto, H. Yoshizawa, Y. Watanabe et al., “Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease,” BMC Nephrology, vol. 13, article 155, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Akimoto, K. Shiizaki, T. Sugase et al., “The relationship between the soluble Klotho protein and the residual renal function among peritoneal dialysis patients,” Clinical and Experimental Nephrology, vol. 16, no. 3, pp. 442–447, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Akimoto, T. Kimura, Y. Watanabe et al., “The impact of nephrectomy and renal transplantation on serum levels of soluble Klotho protein,” Transplantation Proceedings, vol. 45, no. 1, pp. 134–136, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Kurosu, M. Yamamoto, J. D. Clark et al., “Suppression of aging in mice by the hormone Klotho,” Science, vol. 309, no. 5742, pp. 1829–1833, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. D. E. Arking, D. M. Becker, L. R. Yanek et al., “KLOTHO allele status and the risk of early-onset occult coronary artery disease,” The American Journal of Human Genetics, vol. 72, no. 5, pp. 1154–1161, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. D. E. Arking, G. Atzmon, A. Arking, N. Barzilai, and H. C. Dietz, “Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity,” Circulation Research, vol. 96, no. 4, pp. 412–418, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Yamada, F. Ando, N. Niino, and H. Shimokata, “Association of polymorphisms of the androgen receptor and klotho genes with bone mineral density in Japanese women,” Journal of Molecular Medicine, vol. 83, no. 1, pp. 50–57, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. D. J. Friedman, M. Afkarian, H. Tamez et al., “Klotho variants and chronic hemodialysis mortality,” Journal of Bone and Mineral Research, vol. 24, no. 11, pp. 1847–1855, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. G. J. Ko, Y. M. Lee, E. A. Lee et al., “The association of Klotho gene polymorphism with the mortality of patients on maintenance dialysis,” Clinical Nephrology, vol. 80, no. 4, pp. 263–269, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. R. D. Semba, A. R. Cappola, K. Sun et al., “Plasma klotho and cardiovascular disease in adults,” Journal of the American Geriatrics Society, vol. 59, no. 9, pp. 1596–1601, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. R. D. Semba, A. R. Cappola, K. Sun et al., “Plasma klotho and mortality risk in older community-dwelling adults,” Journals of Gerontology—Series A: Biological Sciences and Medical Sciences, vol. 66, no. 7, pp. 794–800, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Nowak, B. Friedrich, F. Artunc et al., “Prognostic value and link to atrial fibrillation of soluble klotho and FGF23 in hemodialysis patients,” PLoS ONE, vol. 9, no. 7, Article ID e100688, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. C. Hu, M. Shi, H. J. Cho et al., “Klotho and phosphate are modulators of pathologic uremic cardiac remodeling,” Journal of the American Society of Nephrology, vol. 26, no. 6, pp. 1290–1302, 2015. View at Publisher · View at Google Scholar
  18. J. Xie, J. Yoon, S. W. An, O. M. Kuro, and C. L. Huang, “Soluble klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate,” Journal of the American Society of Nephrology, vol. 26, no. 5, pp. 1150–1160, 2015. View at Publisher · View at Google Scholar
  19. T. Masuda, M. Murata, S. Honma et al., “Sleep-disordered breathing predicts cardiovascular events and mortality in hemodialysis patients,” Nephrology Dialysis Transplantation, vol. 26, no. 7, pp. 2289–2295, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Shinzato, S. Nakai, Y. Fujita et al., “Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentrations,” Nephron, vol. 67, no. 3, pp. 280–290, 1994. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Thygesen, J. S. Alpert, A. S. Jaffe et al., “Third universal definition of myocardial infarction,” Journal of the American College of Cardiology, vol. 60, no. 16, pp. 1581–1598, 2012. View at Google Scholar
  22. J. J. V. Mcmurray, S. Adamopoulos, S. D. Anker et al., “ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC,” European Journal of Heart Failure, vol. 14, no. 8, pp. 803–869, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. J. D. Easton, J. L. Saver, G. W. Albers et al., “Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American heart association/American stroke association stroke council; council on cardiovascular surgery and anesthesia; council on cardiovascular radiology and intervention; council on cardiovascular nursing; and the interdisciplinary council on peripheral vascular disease,” Stroke, vol. 40, no. 6, pp. 2276–2293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. R. L. Sacco, S. E. Kasner, J. P. Broderick et al., “An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American heart association/American stroke association,” Stroke, vol. 44, no. 7, pp. 2064–2089, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Kitagawa, H. Sugiyama, H. Morinaga et al., “A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease,” PLoS ONE, vol. 8, no. 2, Article ID e56695, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. H. R. Kim, B. Y. Nam, D. W. Kim et al., “Circulating alpha-klotho levels in CKD and relationship to progression,” American Journal of Kidney Diseases, vol. 61, no. 6, pp. 899–909, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Komaba, M. Koizumi, H. Tanaka et al., “Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism,” Nephrology, Dialysis, Transplantation, vol. 27, no. 5, pp. 1967–1969, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Fliser, S. Seiler, G. H. Heine, and M. Ketteler, “Measurement of serum soluble Klotho levels in CKD 5D patients: useful tool or dispensable biomarker?” Nephrology, Dialysis, Transplantation, vol. 27, no. 5, pp. 1702–1703, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Seiler, M. Wen, H. J. Roth et al., “Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease,” Kidney International, vol. 83, no. 1, pp. 121–128, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Seiler, K. S. Rogacev, H. J. Roth et al., “Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2–4,” Clinical Journal of the American Society of Nephrology, vol. 9, no. 6, pp. 1049–1058, 2014. View at Publisher · View at Google Scholar
  31. M. S. Buiten, M. K. de Bie, A. Bouma-de Krijger et al., “Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients,” BMC Nephrology, vol. 15, article 197, 2014. View at Publisher · View at Google Scholar
  32. M. C. Hu, M. Shi, J. Zhang et al., “Renal production, uptake, and handling of circulating αKlotho,” Journal of the American Society of Nephrology, 2015. View at Publisher · View at Google Scholar
  33. K. Lindberg, R. Amin, O. W. Moe et al., “The kidney is the principal organ mediating klotho effects,” Journal of the American Society of Nephrology, vol. 25, no. 10, pp. 2169–2175, 2014. View at Publisher · View at Google Scholar
  34. K. Lim, T.-S. Lu, G. Molostvov et al., “Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23,” Circulation, vol. 125, no. 18, pp. 2243–2255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Rotondi, M. Pasquali, L. Tartaglione et al., “Soluble α-Klotho serum levels in chronic kidney disease,” International Journal of Endocrinology, vol. 2015, Article ID 872193, 8 pages, 2015. View at Publisher · View at Google Scholar
  36. H. Komaba, S. Goto, H. Fujii et al., “Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients,” Kidney International, vol. 77, no. 3, pp. 232–238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Koh, T. Fujimori, S. Nishiguchi et al., “Severely reduced production of klotho in human chronic renal failure kidney,” Biochemical and Biophysical Research Communications, vol. 280, no. 4, pp. 1015–1020, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Yokoyama, A. Imura, I. Ohkido et al., “Serum soluble α-klotho in hemodialysis patients,” Clinical Nephrology, vol. 77, no. 5, pp. 347–351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Shimamura, K. Hamada, K. Inoue et al., “Serum levels of soluble secreted a-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis,” Clinical and Experimental Nephrology, vol. 16, no. 5, pp. 722–729, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Takahashi, H. Komaba, Y. Takahashi et al., “Impact of parathyroidectomy on serum FGF23 and soluble klotho in hemodialysis patients with severe secondary hyperparathyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 4, pp. E652–E658, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. T. B. Drüeke and Z. A. Massy, “Circulating Klotho levels: clinical relevance and relationship with tissue Klotho expression,” Kidney International, vol. 83, no. 1, pp. 13–15, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. M. C. Hu, M. Kuro-o, and O. W. Moe, “Secreted klotho and chronic kidney disease,” Advances in Experimental Medicine and Biology, vol. 728, pp. 126–157, 2012. View at Google Scholar
  43. M. Yamamoto, J. D. Clark, J. V. Pastor et al., “Regulation of oxidative stress by the anti-aging hormone klotho,” Journal of Biological Chemistry, vol. 280, no. 45, pp. 38029–38034, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Akimoto, Y. Morishita, C. Ito et al., “Febuxostat for hyperuricemia in patients with advanced chronic kidney disease,” Drug Target Insights, vol. 8, pp. 39–43, 2014. View at Publisher · View at Google Scholar
  45. T. Finkel and N. J. Holbrook, “Oxidants, oxidative stress and the biology of ageing,” Nature, vol. 408, no. 6809, pp. 239–247, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Saito, T. Yamagishi, T. Nakamura et al., “Klotho protein protects against endothelial dysfunction,” Biochemical and Biophysical Research Communications, vol. 248, no. 2, pp. 324–329, 1998. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Saito, T. Nakamura, Y. Ohyama et al., “In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome,” Biochemical and Biophysical Research Communications, vol. 276, no. 2, pp. 767–772, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Goldsmith, “Negative outcome studies in end-stage renal disease,” Blood Purification, vol. 26, no. 1, pp. 63–66, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Neovius, S. H. Jacobson, J. K. Eriksson, C.-G. Elinder, and B. Hylander, “Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study,” BMJ Open, vol. 4, no. 2, Article ID e004251, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. J. J. Scialla, H. Xie, M. Rahman et al., “Fibroblast growth factor-23 and cardiovascular events in CKD,” Journal of the American Society of Nephrology, vol. 25, no. 2, pp. 349–360, 2014. View at Publisher · View at Google Scholar
  51. O. M. Gutiérrez, M. Mannstadt, T. Isakova et al., “Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis,” The New England Journal of Medicine, vol. 359, no. 6, pp. 584–592, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Faul, A. P. Amaral, B. Oskouei et al., “FGF23 induces left ventricular hypertrophy,” Journal of Clinical Investigation, vol. 121, no. 11, pp. 4393–4408, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. J. H. Ix, R. Katz, B. R. Kestenbaum et al., “Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study),” Journal of the American College of Cardiology, vol. 60, no. 3, pp. 200–207, 2012. View at Publisher · View at Google Scholar · View at Scopus